Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:

MCAC Incontinence Panel Postponed; AMA Commends MCAC Executive Cmte.

This article was originally published in The Gray Sheet

  • News

Executive Summary

The Health Care Financing Administration will postpone the next scheduled meeting of a Medicare Coverage Advisory Committee panel following recent comments made by the MCAC Executive Committee.

You may also be interested in...



MCAC Panel Process Concerns Derail Ratification Of Initial Coverage Opinions

Standard procedures for conducting Medicare Coverage Advisory Committee panel reviews must be developed if future panel recommendations are to hold any chance of ratification, several members of MCAC's Executive Committee maintained at a Dec. 8 meeting.

HCFA Winnows Panel Agenda To Pelvic Floor Stimulation, Biofeedback

Medtronic's Interstim sacral nerve stimulation device for urinary incontinence treatment will not be reviewed as previously scheduled during the Health Care Financing Administration's Jan. 19-20 Medicare Coverage Advisory Committee meeting, agency staffers report.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Table

View full table

Tags:
UsernamePublicRestriction

Register

MT012741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By